Study Provides Detailed Understanding of How Bicarbonate Transporters Work

A new study from researchers at the Icahn School of Medicine at Mount Sinai provides insight into mechanisms of solute carrier transport and inhibition, specifically with anion exchange 1 (AE1). Published in Nature Structural & Molecular Biology, the team found that AE1 can be inhibited by certain drugs, and they set out to uncover the mechanisms behind this interaction. Their findings provide a comprehensive understanding of how bicarbonate transporters function, offering insights into conditions involving red blood cells, including hemolytic anemias.

Human bicarbonate transporters have been a relatively understudied area of research until now. Utilizing advanced cryo-electron microscopy, the team achieved high-resolution structures that revealed the binding of bicarbonate and inhibitors, shedding light on their impact on the transport process. This data empowered them to employ computer simulations to explore millions of compounds that could interact with the substrate binding site.

Through their experiments, they identified a novel group of chemical inhibitors specifically designed for AEI, which is critical for maintaining proper blood function and red blood cell health. These inhibitors could have potential medical applications, particularly in the treatment of various disorders related to solute carrier (SLC) proteins. The significance of this discovery extends to drug development, where SLC proteins play an increasingly important role.

Bin Zhang, a co-author of the study, emphasized the potential for creating new inhibitors for other SLC proteins involved in neurodegenerative diseases, psychiatric disorders, and cancer. The study's findings effectively open the door to developing drug-like molecules at the atomic level, presenting promising prospects for treating a wide range of conditions associated with these proteins.